February 14, 2017 – Ottawa, Ontario – Cannabis Canada Association welcomes Health Canada’s announcement that it will begin conducting random testing of medical cannabis products produced by licensed producers, to provide added assurance to Canadians that they are receiving safe, quality-controlled product.
Cannabis Canada’s first priority, consistent with that of Health Canada, is to ensure that the health and safety of clients is protected. The medical cannabis industry is rigorously regulated. Existing testing and the new spot checks are designed to uncover any issues with quality control. In the event that a quality issue is uncovered, as has recently been the case, there are mechanisms in place to ensure immediate rectification. Moreover, should it be necessary, seed to sale tracking mechanisms are in place to support effective recalls.
“As Canada’s world-leading medical cannabis system develops and grows, it is critical that licensed producers maintain compliance with Health Canada regulations, so that Canadian patients can have confidence in the quality of the medical products they receive,” said Colette Rivet, Executive Director of Cannabis Canada. “This is the path to Canada’s establishment of a strong and sustainable medical cannabis system that can serve as a model to the world.”
Cannabis Canada is committed to working in close collaboration with Health Canada to ensure and enhance the safety, effectiveness and continuous improvement of the legal medical cannabis industry.
Cannabis Canada’s mission is to act as the national voice for our members in their promotion of industry standards, and support the development, growth and integrity of the regulated cannabis industry. The Association has a philosophy of both patient-centric care and improved public health, and is committed to product safety and quality, secure and reliable access and the promotion of the safe and effective use of cannabis.
Cannabis Canada Association